Order Article Reprints

Ioannou P, Katsigiannis A, Papakitsou I, Kopidakis I, Makraki E, Milonas D, Filippatos TD, Sourvinos G, Papadogiannaki M, Lydaki E, et al. Convalescent Plasma Treatment of Patients Previously Treated with B-Cell-Depleting Monoclonal Antibodies Suffering COVID-19 Is Associated with Reduced Re-Admission Rates. Viruses. 2023; 15(3):756. https://doi.org/10.3390/v15030756

Ioannou, Petros, Athanasios Katsigiannis, Ioanna Papakitsou, Ioannis Kopidakis, Eirini Makraki, Dimitris Milonas, Theodosios D. Filippatos, George Sourvinos, Marina Papadogiannaki, Evaggelia Lydaki, and et al. 2023. "Convalescent Plasma Treatment of Patients Previously Treated with B-Cell-Depleting Monoclonal Antibodies Suffering COVID-19 Is Associated with Reduced Re-Admission Rates" Viruses 15, no. 3: 756. https://doi.org/10.3390/v15030756

Ioannou, P., Katsigiannis, A., Papakitsou, I., Kopidakis, I., Makraki, E., Milonas, D., Filippatos, T. D., Sourvinos, G., Papadogiannaki, M., Lydaki, E., Chamilos, G., & Kofteridis, D. P. (2023). Convalescent Plasma Treatment of Patients Previously Treated with B-Cell-Depleting Monoclonal Antibodies Suffering COVID-19 Is Associated with Reduced Re-Admission Rates. Viruses, 15(3), 756. https://doi.org/10.3390/v15030756